Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Inari Medical, Inc. amended revolving credit of from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo with Bank of America, N.A. at BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range.
- Instrument
- revolving credit
- Principal
- from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amo
- Counterparty
- Bank of America, N.A.
- Rate
- BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that range
- Event
- amendment
Exact text from the filing
The Amendment, among other things, (i) increases the amount available under the revolving credit facility from (A) the lesser of $40.0 million and the amount of the borrowing base to (B) the lesser of $75.0 million and the amount of the borrowing base, (ii) provides that advances under the Amended Credit Agreement will bear interest at a rate per annum equal to the BSBY Rate or Base Rate, at the option of the Borrowers, plus a margin that ranges from 0.60% to 1.10% in the case of Base Rate loans and 1.60% to 2.10% in the case of BSBY Rate loans depending on average daily availability, in each case with a floor of 0%, (iii) increases the letter of credit subline from $10.0 million to $18.75 million
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Inari Medical, Inc. entered into Share Purchase Agreement with LimFlow S.A. valued at Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000 (effective 2023-10-31).
- Action
- entry
- Agreement
- merger
- Counterparty
- LimFlow S.A.
- Value
- Initial purchase price of $250,000,000, plus contingent payments up to $165,000,000
- Effective
- 2023-10-31
Exact text from the filing
On October 31, 2023, Lombardi Sub, LLC, a Delaware limited liability company (the “ Purchaser ”) and an indirect wholly-owned subsidiary of Inari Medical, Inc. (the “ Company ”, “ we ” or “ us ”), the Company, as guarantor of Purchaser’s financial obligations, LimFlow S.A., a French limited liability company (société anonyme) (“ LimFlow ”), equity holders of LimFlow (the “ Sellers ”) and Shareholder Representative Services LLC, a Colorado limited liability company (the “ Seller Representative ”), entered into a Share Purchase Agreement (the “ Purchase Agreement ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Inari Medical, Inc. amended Amendment to Loan, Guaranty and Security Agreement with Bank of America, N.A. and other lenders valued at Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75 (effective 2023-11-01).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Bank of America, N.A. and other lenders
- Value
- Increased revolving credit facility from lesser of $40.0 million and borrowing base to lesser of $75
- Effective
- 2023-11-01
Exact text from the filing
On November 1, 2023, the Company, Inari Medical International, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, Inari Medical Latin America, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, each of the lenders signatory thereto (the “ Lenders ”) and Bank of America, N.A. (as the agent for the Lenders, the “ Agent ”) entered into an amendment (the “ Amendment ”) to the Loan, Guaranty and Security Agreement, dated as of September 4, 2020
View on SEC.gov